title: Brodalumab versus ustekinumab in psoriasis.
authors.affiliation: Department of Nuclear Physics, Sub-Nuclear and Radiation, Guglielmo Marconi University, Rome, Italy.
authors.forename: Massimo
authors.initials: M
authors.lastname: Fioranelli
authors.affiliation: University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India.
authors.forename: Maria Grazia
authors.initials: MG
authors.lastname: Roccia
authors.affiliation: Department of Nuclear Physics, Sub-Nuclear and Radiation, Guglielmo Marconi University, Rome, Italy. professor@torellolotti.it.
authors.forename: Torello
authors.initials: T
authors.lastname: Lotti
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D017326:Clinical Trials, Phase III as Topic; D003879:Dermatologic Agents / Q000627:therapeutic use*; D006801:Humans; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D012867:Skin / Q000187:drug effects* / Q000276:immunology; D016896:Treatment Outcome; D000069549:Ustekinumab / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; C571216:brodalumab; D000069549:Ustekinumab
keywords: brodalumab; monoclonal antibody; psoriasis; ustekinumab